Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$0.55 USD

0.55
3,598,115

-0.01 (-1.78%)

Updated May 13, 2024 04:00 PM ET

After-Market: $0.55 0.00 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SGMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Sangamo Therapeutics, Inc. [SGMO]

Reports for Purchase

Showing records 261 - 280 ( 321 total )

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 261

12/02/2013

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 262

12/02/2013

Industry Report

Pages: 52

December 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 263

12/02/2013

Daily Note

Pages: 52

December 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 264

11/05/2013

Company Report

Pages: 7

Ongoing Undetectable Viral Load for 14+ Weeks Suggests to Us that SB-728-T Has Commercial Potential; Reiterate OUTPERFORM and Increasing FV to $15

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 265

11/04/2013

Industry Report

Pages: 49

November and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 266

10/24/2013

Company Report

Pages: 9

Q3 Financials In Line; Waiting for Additional HIV Data; Reiterate OUTPERFORM and $13 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 267

10/02/2013

Industry Report

Pages: 52

October and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 268

09/22/2013

Company Report

Pages: 9

Financing Supports Further HIV and Monogenic Disease Program Development; Reiterate OUTPERFORM and $13 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 269

09/16/2013

Daily Note

Pages: 5

Preliminary SB-728-T Data Presented at ICAAC Shows Functional Control of HIV Virus Without Antiretroviral Therapy; Reiterate OUTPERFORM And $13 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 270

08/27/2013

Daily Note

Pages: 5

Ceregene Acquisition Bolsters Gene Therapy Platform. Reiterate OUTPERFORM And $13 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 271

07/25/2013

Company Report

Pages: 9

Q2 Financials Beat On Higher Collaboration Revenues; Focus On HIV Clinical Results In H2; Reiterate OUTPERFORM And $13 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 272

07/03/2013

Daily Note

Pages: 42

July And Remaining 2013 Catalysts For Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 273

06/03/2013

Daily Note

Pages: 29

June And Remaining 2013 Catalysts For Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 274

05/24/2013

Daily Note

Pages: 6

Platform Technology Further Validated with $6.4MM Grant from CIRM to Develop ZFP Therapeutic for Betathalassemia

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 275

05/15/2013

Daily Note

Pages: 6

SB-728-T Immune Reconstitution Associated With HIV Viral Load And Reservoir Depletion

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 276

05/10/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 277

05/08/2013

Company Report

Pages: 9

Q1 Financials: Extended Cash Runway Covers Potentially Transforming Catalysts; Reiterate OUTPERFORM And $13 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 278

04/21/2013

Daily Note

Pages: 5

No Hints About Interim Phase 2 Viral Load Results In ASGCT Abstracts; Waiting For May 15th Presentation; Reiterate OUTPERFORM And $13 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 279

03/06/2013

Company Report

Pages: 9

CROI Data Could Be A Prelude To Positive Preliminary Phase 2 HIV Results At ASGCT In May; Increasing FV To $13 For HIV Progress And Time Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Sangamo Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 280

03/04/2013

Industry Report

Pages: 32

Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party